Introduction and study rationale {#s1}
================================

Asthma is a chronic inflammatory disease of the airways \[[@C1]\]. The inflammation is variable in terms of intensity and is heterogeneous, with well-characterised subtypes that have different responses to therapy \[[@C1], [@C2]\]. In parallel, variability in lung function, asthma symptoms and reliever medication use are commonly observed over days and weeks \[[@C3]--[@C5]\]. Often, these periods, beyond baseline day-to-day or week-to-week variability, are interspersed with significant exacerbations of symptoms \[[@C6]\], necessitating increased reliever use and, potentially, the use of oral corticosteroids \[[@C7]\].

Treatment with inhaled corticosteroids (ICS) is the cornerstone of asthma management \[[@C7]\] and treatment strategies targeted at inflammation (*via* maintenance of a normal airway eosinophil count) have been shown to reduce the risk of severe exacerbations compared with strategies based on assessment of symptoms, lung function and use of rescue treatment \[[@C8]\]. However, many patients, regardless of the underlying disease severity, are not adherent with such treatment and rely on short-acting β~2~-agonists (SABAs) for rapid relief of asthma symptoms \[[@C9]\]. Such over-reliance on SABAs is a concern since their excessive use may worsen asthma control and increase the risk of fatal or near-fatal asthma \[[@C10], [@C11]\]. A SABA does not address the underlying inflammation and increases the risk of exacerbations \[[@C12]\]. In addition, even in patients whose disease is apparently controlled and who are adherent to maintenance medication, exacerbations may still occur \[[@C9]\]. This suggests that, in such a variable condition, patients\' requirement for anti-inflammatory therapy varies and, in turn, represents an argument in favour of providing increased doses of ICS when symptoms worsen. To this end, a combination of budesonide/formoterol (ICS/fast-onset but long-acting β~2~-agonist (LABA)) as maintenance and reliever therapy has been studied in several randomised controlled trials in patients with moderate-to-severe asthma \[[@C5], [@C13]--[@C16]\]. Results from these trials have demonstrated that as-needed use of budesonide/formoterol as an anti-inflammatory reliever in addition to daily maintenance therapy is highly effective in reducing the risk of severe exacerbations, with up to a 47% reduction *versus* comparator regimens that utilise a SABA as a reliever \[[@C5], [@C13], [@C16]\]. In addition, as-needed budesonide/formoterol has been evaluated as a treatment option for patients with mild asthma, as assessed in the SYGMA (Symbicort Given as Needed in Mild Asthma) programme \[[@C17], [@C18]\], the PRACTICAL (Personalised Asthma Combination Therapy: with Inhaled Corticosteroid and Fast Onset Long-Acting Beta Agonist) study \[[@C19]\] and the Novel START (Novel Symbicort Turbuhaler Asthma Reliever Therapy) study \[[@C20]\]. In the latter study, the risk of severe exacerbations was lower in the as-needed budesonide/formoterol group compared with as-needed SABA, a finding that was paralleled by a reduction in exhaled nitric oxide fraction (*F*~ENO~), consistent with an effect of as-needed budesonide/formoterol on airway inflammation \[[@C20]\].

Hypothesis of the STIFLE study: use of anti-inflammatory reliever therapy in the "window of opportunity" {#s2}
========================================================================================================

The benefits of anti-inflammatory reliever therapy in reducing the risk of exacerbations are hypothesised to be due to additional anti-inflammatory ICS therapy received at pivotal times \[[@C21]\], specifically during the "window of opportunity" when inflammation-driven symptoms start to worsen ([figure 1](#F1){ref-type="fig"} and [supplementary video](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00333-2019.figures-only#fig-data-supplementary-materials)) \[[@C22], [@C23]\]. This is based on the work of T[attersfield]{.smallcaps} *et al.* \[[@C23]\], who evaluated all severe exacerbations that occurred in the FACET (Formoterol and Corticosteroids Establishing Therapy) study. Exacerbations were characterised by a gradual fall in peak expiratory flow (PEF) over 5--7 days, followed by a more rapid fall over 2--3 days prior to an exacerbation. Furthermore, the change in PEF occurred in parallel with an increase in symptoms and the use of SABA reliever, suggesting that a 2--3-day window of opportunity exists when patients experience deteriorating symptoms and lung function but have not yet deteriorated to the stage of requiring oral corticosteroids. Indeed, a *post hoc* analysis of *F*~ENO~ data from the CHARISM (Childhood Asthma Respiratory Inflammatory Status Monitoring) study showed an increase in *F*~ENO~ ∼10 days before a moderate exacerbation, with a significant increase 3 days beforehand \[[@C24]\]. Together, these findings highlight an early opportunity to adjust treatment with an increase in ICS to target the underlying flare-up of airway inflammation, thereby arresting progression to exacerbation. In addition, against a background of budesonide/formoterol maintenance therapy, as-needed formoterol demonstrated better exacerbation control than a SABA \[[@C14]\], likely due to a stabilising effect on airway smooth muscle. Furthermore, LABAs may be particularly active against noneosinophilic exacerbations \[[@C25]\].

![Proposed hypothesis of the mechanism of a) short-acting β~2~-agonist (SABA) reliever and b) as-needed budesonide (BUD)/formoterol (FORM) as anti-inflammatory reliever therapy during worsening of asthma symptoms that precedes an exacerbation. The effects of FORM are likely to be more complex and are not presented in the graphs. SABA treats only symptoms and not the underlying inflammation. Anti-inflammatory reliever therapy treats both symptoms and the underlying inflammation. Dashed lines indicate asthma worsening in patients with SABA reliever use.](00333-2019.01){#F1}

However, supporting mechanistic evidence has not yet been described for as-needed budesonide/formoterol, specifically the nature of the variations and temporal dynamics (patterns or trends with respect to time) of airway inflammation, symptoms, lung function and reliever use, both over time and during periods of symptom worsening. Consequently, the STIFLE study (EudraCT identifier number 2018-003467-64) has been designed to characterise the day-to-day relationship between such parameters, and specifically in relation to worsening of symptoms in patients with asthma receiving as-needed budesonide/formoterol anti-inflammatory reliever or a SABA, against a background of budesonide/formoterol maintenance therapy.

Design of the STIFLE study {#s3}
==========================

STIFLE is a phase IV, randomised, active-comparator, open-label, parallel-group, multicentre, exploratory, 24-week study in adult asthma patients (≥18 years of age) receiving Global Initiative for Asthma 2018 \[[@C26]\] step 3 or step 4 treatment (low- or medium-dose ICS/LABA only). The study aims to characterise variability in inflammation (*F*~ENO~), symptoms, lung function and reliever use, on a daily basis, over time (primary objective) and in the period surrounding an event (secondary objective). Events include severe exacerbation, Composite Endpoint for Exacerbations (CompEx) \[[@C27]\], a single day with six or more occasions of reliever medication use and *F*~ENO~ \>50 ppb ([table 1](#TB1){ref-type="table"}). Key inclusion and exclusion criteria are shown in [table 2](#TB2){ref-type="table"}. This study will consist of a screening visit (visit 1), a 2-week run-in period, a baseline visit (visit 2) and a 24-week treatment period (visits 3 and 4) ([figure 2](#F2){ref-type="fig"}). During the run-in period, patients will receive maintenance budesonide/formoterol 100/6 µg or 200/6 µg dry-powder inhaler, two inhalations twice daily (based on ongoing low- or medium-dose ICS/LABA, respectively, at study entry) and SABA reliever (salbutamol 100 µg) as needed. At visit 2 (baseline visit, week 1), eligible patients will be randomised 1:1 (stratified by ongoing low- or medium-dose of ICS/LABA at study entry) to receive maintenance budesonide/formoterol (100/6 µg or 200/6 µg, two inhalations twice daily) with either as-needed budesonide/formoterol (same dose as maintenance) or salbutamol (100 µg) as reliever for 24 weeks. Additional visits will be scheduled if a patient meets any of the criteria for an event during the treatment period, including the first occurrence of a severe exacerbation, symptom worsening (decrease in PEF, increase in reliever use or asthma symptoms) or a single day with six or more occasions of reliever medication use. Informed consent will be obtained from all patients prior to initiation of study-related procedures, sampling and analysis.

###### 

STIFLE study objectives and endpoints

  **Objectives**                                                                                                                                                                                          **Endpoints**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Primary**                                                                                                                                                                                             
   To characterise descriptively^\#^ the relationship between airway inflammation, asthma symptoms, lung function and reliever use, in the two treatment arms measured daily over 24 weeks of treatment   Individual patient profiles of daily variations over time in *F*~ENO~ (morning), asthma symptom scores (morning and evening), PEF and FEV~1~ (morning and evening), and reliever use
  **Secondary**                                                                                                                                                                                           
   To characterise descriptively^\#^ airway inflammation, asthma symptoms, lung function and reliever use profiles surrounding an event in the two treatment arms                                         Individual patient profiles of daily variations over time in *F*~ENO~ (morning), asthma symptom scores (morning and evening), PEF and FEV~1~ (morning and evening), and reliever use between 14 days prior and 28 days after an event. Events include severe exacerbation^¶^, CompEx (full criteria) \[26\], single day (in 24 h) with six or more occasions of reliever medication use and *F*~ENO~ \>50 ppb
  **Exploratory**                                                                                                                                                                                         
   To describe patterns of inflammatory biomarkers in the two treatment arms at the start of an event^+^ (and every 4 days up to 12 days)                                                                 Individual patient profiles of inflammation biomarkers (blood biomarkers including eosinophils, EDN and CRP; sputum and nasal biomarkers) at the start of an event (and every 4 days up to 12 days)
   To characterise descriptively the daily variations in nasal biomarker measures during the first 30 days of treatment in the two treatment arms                                                         Individual patient profiles of daily variations over time in nasal biomarkers during the first 30 days of treatment (subset of 30 patients)

Severe exacerbation events will be recorded, as they occur, on a case report form. Other events will be retrospectively defined and analysed based on the data collected during the study. *F*~ENO~: exhaled nitric oxide fraction; PEF: peak expiratory flow; FEV~1~: forced expiratory volume in 1 s; CompEx: Composite Endpoint for Exacerbations; EDN: eosinophil-derived neurotoxin; CRP: C-reactive protein. ^\#^: this study has not been designed or powered to test any statistical hypothesis relating to a difference between the treatment arms; instead, airway inflammation, symptoms, lung function and reliever use profiles will be assessed descriptively and visually and will be modelled for each patient individually and by treatment, both over the 24-week period and during the time surrounding the various events. ^¶^: use of systemic corticosteroids for ≥3 days, an emergency department visit due to asthma that requires systemic corticosteroids or inpatient hospitalisation due to asthma. ^+^: events of interest include the first occurrence of either a severe exacerbation, symptom worsening (deterioration in two or more variables for two or more consecutive days: ≥15% decrease in PEF, ≥1.5 times increase in inhalations of reliever medication or ≥1 increase in asthma symptom score (or the absolute maximum score of 3), in the morning or evening, as compared with baseline), or a single day (in 24 h) with six or more occasions of reliever use.

###### 

Key inclusion and exclusion criteria

  **Inclusion criteria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             **Exclusion criteria**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Male and/or female patients aged ≥18 yearsPhysician-diagnosed asthma for ≥6 months prior to visit 1Use of low- or medium-dose ICS/LABA^\#^ for ≥3 months prior to visit 1Worsening of asthma symptoms requiring overuse^¶^ of reliever medication at least once within 30 days prior to visit 1Patient-reported history of one or more severe asthma exacerbations requiring treatment with systemic corticosteroids during the 12 months prior to visit 1, except in the previous 30 daysAbility to perform *F*~ENO~ and spirometry assessments at home and complete an asthma symptom diary on a regular basis   Patients with any significant disease or disorder or evidence of drug/substance abuse that would pose a risk to patient safety, interfere with study conduct or impact study resultsAny asthma worsening requiring a change in treatment other than the prescribed reliever medication within 30 days prior to visit 1Medical history of life-threatening asthma, including intubation and admission to an intensive care unitMedical conditions (except allergic rhinitis) or medications (except ICS) that may influence *F*~ENO~Concurrent respiratory disease (*e.g.* cystic fibrosis, idiopathic pulmonary fibrosis or pulmonary arterial hypertension)Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to visit 1 or during screening/run-in periodA severe exacerbation (resulting in ≥3 days of oral corticosteroids (or one depot intramuscular injection of glucocorticosteroid), an urgent care or emergency room visit resulting in treatment with systemic corticosteroids or an inpatient hospitalisation due to asthma) within 30 days prior to screeningAny disease, other than asthma, or procedure that may necessitate the use of oral/systemic corticosteroids during the treatment periodCurrent tobacco smoking or a history of smoking for ≥10 pack-years

ICS: inhaled corticosteroid; LABA: long-acting β~2~-agonist; *F*~ENO~: exhaled nitric oxide fraction. ^\#^: low ICS doses (daily): beclometasone dipropionate hydrofluoroalkane (HFA) (100--200 µg), budesonide dry-powder inhaler (DPI) (200--400 µg), ciclesonide HFA (80--160 µg), fluticasone furoate DPI (100 µg), fluticasone propionate DPI or HFA (100--250 µg), mometasone furoate (110--220 µg) and triamcinolone acetonide (400--1000 µg); medium ICS doses (daily): beclometasone dipropionate HFA (\>200--400 µg), budesonide DPI (\>400--800 µg), ciclesonide HFA (\>160--320 µg), fluticasone propionate DPI or HFA (\>250--500 µg), mometasone furoate (\>220--440 µg) and triamcinolone acetonide (\>1000--2000 µg). ^¶^: overuse was defined as more than the standard use of reliever for individual patients.

![Study design. BMI: body mass index. ^\#^: patients on low-dose inhaled corticosteroid (ICS)/long-acting β~2~-agonist (LABA) at study entry will receive budesonide (BUD)/formoterol (FORM) 100/6 µg and those on medium-dose ICS/LABA at study entry will receive BUD/FORM 200/6 µg. ^¶^: randomisation criteria are adherence (completed ≥80% of asthma assessments (exhaled nitric oxide fraction (*F*~ENO~) and spirometry measurements, and completing the asthma symptom diary) at home during the run-in period) and reliever medication use (used reliever medication for 2--8 days out of the last 10 days of the run-in period). ^+^: event visit assessments are prior and concomitant medication (days 1 and 12), serious adverse events (AEs) and AEs leading to treatment discontinuation, clinical chemistry, urinalysis, haematology (including eosinophils), spontaneous sputum for inflammatory biomarkers, nasal absorption samples for inflammatory biomarkers, blood sample (eosinophil-derived neurotoxin and C-reactive protein), plasma and serum samples for exploratory biomarkers. ^§^: daily assessments at home are *F*~ENO~, peak expiratory flow (PEF) and forced expiratory volume in 1 s (FEV~1~), and completing the asthma symptom diary before taking the study medication in the morning; and PEF and FEV~1~, and completing the asthma symptom diary before taking the study medication in the evening.](00333-2019.02){#F2}

All patients will be provided with a kit containing a smartphone and four devices (a *F*~ENO~ monitoring device (Vivatmo Me; Bosch, Waiblingen, Germany), a spirometer (Spirobank Smart; MIR, Rome, Italy) and two inhaler sensors (SmartTurbo and SmartTouch; Adherium, Auckland, New Zealand)) connected to the smartphone *via* the STIFLE application (AstraZeneca, Cambridge, UK) and will receive training on its use. Daily, at home, patients will perform *F*~ENO~ measurements (morning) and spirometry assessments (PEF and forced expiratory volume in 1 s (FEV~1~), morning and evening) and complete an asthma symptom diary that includes reliever medication use (morning and evening). Data from these four devices and an embedded asthma symptom diary will be recorded in the STIFLE application through an integrated approach ([figure 3](#F3){ref-type="fig"}). ∼30 patients who agree to participate in a nasal biomarker substudy of STIFLE will be shown how to collect a nasal absorption sample (synthetic absorptive matrix (SAM) \[[@C28]\]), and will be provided with a kit and instructions for collecting the samples at home. These patients will collect daily morning nasal samples for the first 30 days of randomised treatment for the evaluation of inflammatory biomarkers.

![Integrated approach to data collection. PEF: peak expiratory flow; FEV~1~: forced expiratory volume in 1s; *F*~ENO~: exhaled nitric oxide fraction. ^\#^: the patient and the investigator will receive alerts from the STIFLE system regarding event visits (in relation to the exploratory objective event) due to symptom worsening (based on peak expiratory flow (PEF), reliever use and symptom score criteria) or due to a single day with six or more occasions of reliever medication use. Patients will also be instructed to contact the study site to arrange an event visit if they experience a severe exacerbation. Patients and investigators will be blinded to all data collected from these devices. Asthma symptoms during the night and day will be recorded by the patient twice daily in the asthma symptom diary, according to the following scoring system: 0, no asthma symptoms; 1, "you are aware of your asthma symptoms, but you can easily tolerate the symptoms"; 2, "your asthma is causing you enough discomfort to cause problems with normal activities (or with sleep)"; 3, "you are unable to do your normal activities (or to sleep) because of your asthma".](00333-2019.03){#F3}

At all clinic visits, FEV~1~ will be assessed (by clinic spirometry equipment), safety (adverse events) will be evaluated, and blood samples will be collected for haematology (including eosinophils), clinical chemistry and C-reactive protein analyses. 60--80 patients will be randomised from three sites in the UK to achieve ≥50 patients who will complete the 24-week study. It is anticipated that half of these patients will meet the criteria for an event.

A short review: *F*~ENO~ {#s4}
========================

Daily measurement of *F*~ENO~ is an important methodological component of the STIFLE study. *F*~ENO~ is a simple, noninvasive, quantitative, highly sensitive and safe measure of airway inflammation \[[@C29]\]. *F*~ENO~ is a surrogate marker for eosinophilic airway inflammation and is used to determine the potential need for and likelihood of response to ICS, to optimise the doses of anti-inflammatory medications, and to unmask poor adherence to ICS \[[@C29]\]. A strength of the STIFLE study is that we will measure *F*~ENO~ concentrations daily, against a background of maintenance ICS therapy, to determine if variability in *F*~ENO~ around the time of an exacerbation can be detected and, therefore, whether it is a useful biomarker of type 2 inflammation in a cohort of treated patients with moderate asthma.

How will the STIFLE study help understand the day-to-day relationship between airway inflammation, symptoms and lung function in patients with asthma? {#s5}
======================================================================================================================================================

To our knowledge, STIFLE will be the first study specifically designed to investigate daily airway inflammatory patterns and associated variability in symptoms, lung function and reliever medication use in patients with asthma. An increase in airway inflammation is thought to contribute to worsening of asthma symptoms and deterioration in lung function, requiring the use of reliever medication. However, the time perspective of various parameters before and after asthma worsening is largely unknown, including the order of appearance, magnitude and timeframe in relation to worsening. Therefore, the STIFLE study will help clarify these differences and provide an understanding of the temporal dynamics of these parameters, and specifically in relation to asthma worsening.

High "as-needed" reliever use is a robust measure of asthma instability \[[@C22]\]. Results from an exploratory analysis of two randomised controlled trials reported that budesonide/formoterol maintenance and anti-inflammatory reliever therapy reduced the incidence of high reliever use episodes (more than six inhalations a day) and exacerbation burden immediately following these high-use episodes compared with ICS/LABA maintenance plus SABA reliever therapy \[[@C22]\]. Consequently, STIFLE will also help establish whether the hypothesised mechanistic benefit of as-needed budesonide/formoterol as anti-inflammatory reliever relates to the timely and rapid suppression of airway inflammation (and related symptoms) by ICS during the window of opportunity \[[@C21], [@C22]\], as compared with only symptom relief provided by a SABA ([figure 1](#F1){ref-type="fig"}). The concentration of ICS in lung tissue has been shown to decline over time (between maintenance doses) \[[@C30]\], with concentrations being ∼10% of peak values within 6 h of inhalation; thus, as-needed ICS may help restore concentrations when the levels of ICS are suboptimal between scheduled maintenance doses \[[@C14]\]. The importance of increasing ICS dosing frequency is supported by the results of a crossover study in 34 adult asthma outpatients where greater efficacy was consistently observed with budesonide four times daily dosing compared with two times daily dosing, while providing the same total daily dose \[[@C31]\]. In addition to the timely increase in ICS dose, the rapid onset of action of ICS is of particular importance, with a wealth of evidence supporting the rapid anti-inflammatory effect of inhaled budesonide (with or without formoterol) \[[@C32]--[@C35]\]. Indeed, results from a randomised controlled trial in 41 patients with stable asthma reported a significant reduction in sputum eosinophils and an improvement in airway responsiveness within 6 h of budesonide inhalation \[[@C32]\]. Furthermore, a systemic anti-inflammatory effect on circulating lymphocytes within 30 min of inhalation with budesonide/formoterol has been demonstrated \[[@C34]\]. Additionally, budesonide/formoterol has been reported to prevent asthma deterioration and significantly improve baseline FEV~1~ at 30 min following a low-dose allergen exposure in patients with intermittent allergic asthma \[[@C35]\].

Notably, the STIFLE study will incorporate several important methodological components. The main outcomes will be based on daily measurements, including local airway inflammation as measured by *F*~ENO~ concentrations taken at home. To date, very few studies have evaluated *F*~ENO~ in the setting of acute exacerbations and those that have report varying results \[[@C36]--[@C38]\]. Results from a cross-sectional study in a paediatric emergency department reported that *F*~ENO~ concentrations during an exacerbation did not correlate with asthma severity and had limited utility in the management of acute asthma \[[@C36]\]. In contrast, in adult patients with moderate-to-severe asthma, a significant increase in *F*~ENO~ concentrations during exacerbations compared with baseline in certain patients was reported \[[@C37]\]. In a sample of emergency department patients with acute exacerbations of asthma, *F*~ENO~ measurements were poorly reproducible and did not correlate with asthma severity \[[@C38]\]. However, a significant increase in *F*~ENO~ was reported during 3 days before until 4 days after moderate exacerbations in children with asthma \[[@C24]\]. The results from STIFLE are therefore expected to contribute to this knowledge base. Although *F*~ENO~ measurements have been implemented in many asthma trials, including studies utilising daily, domiciliary methods for capturing *F*~ENO~ \[[@C39], [@C40]\], a novel aspect of this study is that daily home assessments of *F*~ENO~ will be used to determine variability and to compare with other parameters (lung function, reliever use and symptoms) in a real-time environment to assess maintenance plus SABA *versus* maintenance plus anti-inflammatory reliever therapy over 6 months.

A potential limitation of using *F*~ENO~ measurements is that rhinitis and allergic comorbidities in patients with asthma may also lead to changes in *F*~ENO~ levels \[[@C41]\]. However, in addition to *F*~ENO~, other biomarkers of inflammation, such as sputum and blood eosinophils, eosinophil-derived neurotoxin, and nasal absorption biomarkers, will also be measured to explore patterns of inflammation. As patients will be performing *F*~ENO~ and spirometry assessments at home, it is necessary that they use these devices correctly. Spirometers can be difficult to use in the community and challenging to interpret. However, all patients are trained on device use. Moreover, there is a precedence for the use of the spirometer in the home environment \[[@C42], [@C43]\].

Another important feature of the study design of STIFLE is the examination of the temporal dynamics of clinical parameters and local inflammation in relation to an event ([figure 4](#F4){ref-type="fig"}), which may provide insights into the inflammatory mechanism of worsening symptoms and lung function and highlight the benefits of an anti-inflammatory reliever compared with a SABA reliever. Notably, STIFLE will include patients on a background of ICS/LABA maintenance since variability in lung function, asthma symptoms and reliever medication use are also observed in patients receiving such therapy \[[@C5], [@C9]\], many of whom continue to be at risk of exacerbations even when adherent to therapy \[[@C44]\].

![Examination of endpoints over 24 weeks and specifically in relation to an event. The graphs are for representation only. The variables may or may not show parallel changes at a specific time point. Results from the STIFLE study would potentially provide an understanding of the temporal dynamics of these parameters.](00333-2019.04){#F4}

STIFLE will also be among one of the first prospective studies to use CompEx, an extended definition of asthma exacerbations that combines diary-based events (clinically relevant asthma deteriorations) with the traditional definition of severe exacerbations \[[@C27]\]. Since severe exacerbations are rare events, clinical trials using such events as the primary outcome measure require large sample sizes and a long study duration to evaluate treatment effects. Thus, CompEx, which mirrors results observed with the severe exacerbation-validated outcome \[[@C27]\], was incorporated into the STIFLE study because it allows for the evaluation of clinically relevant worsening in this clinical trial of short duration and with relatively few patients.

Conclusion {#s6}
==========

In summary, the temporal dynamics of clinical parameters and airway inflammation are largely unknown in patients with asthma, and the mechanistic evidence for the anti-inflammatory effect of as-needed budesonide/formoterol has not been described. STIFLE is expected to provide insights into the real-time day-to-day relationship between airway inflammation, lung function, asthma symptoms and reliever use in such patients, including the temporal dynamics of various parameters surrounding events. Results will further elucidate the anti-inflammatory effect of budesonide/formoterol as an anti-inflammatory reliever against a background of regular maintenance therapy.
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